Sidhu Harpreet Singh, Srinivasa R, Sadhotra Akshay
Department of Pharmacology, M.M. Institute of Medical Sciences and Research, M.M. University, Ambala, India.
Department of Neurology, M.S. Ramaiah Memorial Hospital, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Epilepsy Res. 2018 Jan;139:20-27. doi: 10.1016/j.eplepsyres.2017.10.016. Epub 2017 Oct 28.
To investigate the development of reproductive endocrine changes in Indian women with epilepsy initiating on either Valproate (VPA) or Lamotrigine (LTG) monotherapy.
Reproductive hormonal profiles, hirsutism, ovarian morphology by ultrasonography and menstrual cycle data in newly diagnosed women with epilepsy taking VPA (n=34) or LTG (n=32) monotherapy were compared. None of the women were receiving hormonal contraception. Patients gave details of seizure type and frequency, medical and drug history. Body weight and fasting insulin, glucose, testosterone, dihyroepiandrosterone sulfate (DHEAS), androstenedione, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH) were measured. Body mass index, free androgen index and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Longitudinal evaluations were done at 6th month and at 12th month. After 12th month some VPA-treated women were replaced with LTG and further followed-up twice in next six months.
The mean testosterone level was significant increased in VPA-treated women at 6th month (p=0.03), then at 12th month (p=0.01). More women in the valproate group than the lamotrigine group developed hirsutism (p=0.06), menstrual disturbances (p=0.02) and PCOS (p=0.001). Before valproate therapy, 32% of the patients were obese, this percentage rose to 47% after treatment (p=0.03). A significant positive correlation was existed between obesity (BMI >25) and the development of menstrual disturbances (p=0.006), serum testosterone levels (p=0.02) and PCOS (p=0.03). Insulin resistance (HOMA-IR >2.5) was significant correlated with menstrual disturbances (p=0.03) and serum testosterone levels (p=0.02). Substitution of VPA with LTG results in significant reduction in mean testosterone levels (p=0.005) and means body weight at 6th month (p=0.01).
Long-term valproate therapy in Indian women with epilepsy was associated with development of menstrual disturbances, alterations in reproductive hormonal function and increased the risk to developed PCOS.
研究采用丙戊酸(VPA)或拉莫三嗪(LTG)单药治疗的印度癫痫女性患者生殖内分泌变化的发展情况。
比较新诊断的接受VPA单药治疗(n = 34)或LTG单药治疗(n = 32)的癫痫女性患者的生殖激素水平、多毛症、超声检查的卵巢形态及月经周期数据。所有女性均未接受激素避孕。患者提供癫痫发作类型和频率、病史及用药史的详细信息。测量体重、空腹胰岛素、血糖、睾酮、硫酸脱氢表雄酮(DHEAS)、雄烯二酮、性激素结合球蛋白(SHBG)、促黄体生成素(LH)、促卵泡生成素(FSH)。计算体重指数、游离雄激素指数和胰岛素抵抗稳态模型评估(HOMA-IR)。在第6个月和第12个月进行纵向评估。12个月后,部分接受VPA治疗的女性换用LTG,并在接下来的6个月内进行两次随访。
VPA治疗组女性在第6个月时平均睾酮水平显著升高(p = 0.03),第12个月时依然显著升高(p = 0.01)。VPA组出现多毛症(p = 0.06)、月经紊乱(p = 0.02)和多囊卵巢综合征(PCOS)(p = 0.001)的女性多于LTG组。在接受丙戊酸治疗前,32%的患者肥胖,治疗后这一比例升至47%(p = 0.03)。肥胖(BMI>25)与月经紊乱的发生(p = 0.006)、血清睾酮水平(p = 0.02)和PCOS(p = 0.03)之间存在显著正相关。胰岛素抵抗(HOMA-IR>2.5)与月经紊乱(p = 0.03)和血清睾酮水平(p = 0.02)显著相关。VPA换用LTG可使第6个月时的平均睾酮水平(p = 0.005)和平均体重(p = 0.01)显著降低。
印度癫痫女性长期接受丙戊酸治疗与月经紊乱、生殖激素功能改变及发生PCOS的风险增加有关。